Circadia

Predictive Technology for Proactive Senior Care

Operating in digital health based in United Kingdom, Circadia was founded in 2016.

Profile

Circadia enables the early detection of respiratory complications, the third leading cause of death, to save patient lives. The company provides an inexpensive, medical-grade, frictionless solution to clinicians in order to help improve patient outcomes, reduce provider workload and reduce the cost of care. Circadia’s C100 Contactless Respiratory Monitoring System conveniently monitors patients with acute respiratory illnesses both in-facility and remotely at home. During the pandemic, Circadia is delivering 2,000 C100 devices to health care facilities to minimize health worker contact and exposure to COVID-19, and is on track to tripling its manufacturing capacity. This follows the FDA’s latest guidance to expand the availability and capability of non-invasive remote respiratory monitoring devices. The company has started deploying its AI-powered C100 with a large hospital in Los Angeles and is in ongoing discussions with global governments and health systems. Read more here.

As a business in digital health, Circadia is listed here with the public details available about it.

The business is associated with United Kingdom.

Directory data places it at the SOSV portfolio company stage.

Recorded headcount: 2-10 employees.

Public records show total funding of about $1M.

Website: circadia.health